Malaysia, Nigeria, Peru, Zambia, and the European Medicines Agency have approved CAB for PrEP; ViiV also made submissions in Canada, Colombia, and the United Kingdom. There are now 13 regulatory approvals and 15 additional submissions that are pending.
